Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets (Callithrix jacchus)
Authors:
Open Access
- 22 July 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-15
Abstract
While sustained-release buprenorphine (BSR) is used as a long-lasting opioid analgesic in common marmosets (Callithrix jacchus), there are no published studies on pharmaceutical-grade extended-release buprenorphine options such as Ethiqa XR (EXR) for this species. However, BSR is a compounded product and has been reported to cause injection site reactions in multiple species, including marmosets. Additionally, now with the availability of EXR, a pharmaceutical-grade veterinary product, the use of BSR in laboratory animals is not compliant with the Guide for the Care and Use of Laboratory Animals (Guide) unless scientifically justified and approved by the IACUC. We compared pharmacokinetic and safety profiles of BSR (0.15 mg/kg) and EXR (0.1–0.2 mg/kg) administered subcutaneously to adult marmosets. Blood was collected by venipuncture of the saphenous vein at multiple time points (0.25–72 h) and analyzed by liquid chromatography-tandem mass spectrometry (LC–MS/MS). EXR between 0.1 and 0.2 mg/kg resulted in a dose-dependent increase in Cmax (1.43–2.51 ng/mL) and were not statistically different from BSR (1.82 ng/mL). Tmax, lambdaz, and t1/2 were not statistically different between formulations. Mean plasma buprenorphine concentrations for BSR and EXR exceeded the therapeutic threshold (0.1 ng/mL) within 0.25 h and lasted for > 72 h. Mild sedation, but neither respiratory depression nor ataxia, was observed for both formulations. BSR injection sites had significantly higher histopathological scores compared to EXR. Video recordings for monitoring drug-induced behavioral changes showed increased animal activity levels after BSR and EXR versus saline controls. Norbuprenorphine, a buprenorphine metabolite associated with respiratory depression, was detected in the plasma after BSR and EXR administration as well as by in vitro liver microsome assays. In conclusion, we recommend using EXR over BSR as a long-lasting buprenorphine analgesic in marmosets because EXR is a pharmaceutical-grade formulation that is compliant with FDA guidelines and the Guide as well as exhibits comparable PK and safety profiles as BSR.Keywords
Funding Information
- ACLAM Foundation (030681-00001)
- National Institute on Drug Abuse (75N95019C00016)
- National Institutes of Health (P30-ES002109)
This publication has 51 references indexed in Scilit:
- An animal model that reflects human disease: the common marmoset (Callithrix jacchus)Current Opinion in Virology, 2012
- Buprenorphine Metabolites, Buprenorphine-3-glucuronide and Norbuprenorphine-3-glucuronide, Are Biologically ActiveAnesthesiology, 2011
- Gender differences in pharmacokinetics of maintenance dosed buprenorphineDrug and Alcohol Dependence, 2011
- Efficacy of oral transmucosal and intravenous administration of buprenorphine before surgery for postoperative analgesia in dogs undergoing ovariohysterectomyJournal of the American Veterinary Medical Association, 2011
- The Effects of Repeated Opioid Administration on Locomotor Activity: I. Opposing Actions of μ and κ ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Two years after in vivo implantation of poly(DL‐lactide‐ε‐caprolactone) nerve guides: Has the material finally resorbed?Journal of Biomedical Materials Research Part A, 2008
- Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine After a Single Intravenous Administration in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Crossover StudyClinical Therapeutics, 2007
- The In Vivo Glucuronidation of Buprenorphine and Norbuprenorphine Determined by Liquid Chromatography-Electrospray Ionization-Tandem Mass SpectrometryTherapeutic Drug Monitoring, 2006
- IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYSDrug Metabolism and Disposition, 2005
- MU receptor-serotonin link in opioid induced hyperactivity in miceLife Sciences, 1990